Effects of an early intensive blood pressure-lowering strategy using remifentanil and dexmedetomidine in patients with spontaneous intracerebral hemorrhage : a multicenter, prospective, superiority, randomized controlled trial
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Anesthesiologists..
BACKGROUND: Although it has been established that elevated blood pressure and its variability worsen outcomes in spontaneous intracerebral hemorrhage, antihypertensives use during the acute phase still lacks robust evidence. A blood pressure-lowering regimen using remifentanil and dexmedetomidine might be a reasonable therapeutic option given their analgesic and anti-sympathetic effects. The objective of this superiority trial was to validate the efficacy and safety of this blood pressure-lowering strategy that uses remifentanil and dexmedetomidine in patients with acute intracerebral hemorrhage.
METHODS: In this multicenter, prospective, single-blinded, superiority randomized controlled trial, patients with intracerebral hemorrhage and systolic blood pressure (SBP) ≥150 mmHg were randomly allocated to the intervention group (a preset protocol with a standard guideline management using remifentanil and dexmedetomidine) or the control group (standard guideline-based management) to receive blood pressure-lowering treatment. The primary outcome was the SBP control rate (<140 mmHg) at 1 h posttreatment initiation. Secondary outcomes included blood pressure variability, neurologic function and clinical outcomes.
RESULTS: A total of 338 patients were allocated to the intervention (n = 167) or control group (n = 171). The SBP control rate at 1 h posttreatment initiation in the intervention group was higher than that in controls (101/161, 62.7% vs. 66/166, 39.8%, difference 23.2%, 95% CI, 12.4 to 34.1%, P < 0.001). Analysis of secondary outcomes indicated that patients in the intervention group could effectively reduce agitation while achieving lighter sedation, but no improvement in clinical outcomes was observed. Regarding safety, the incidence of bradycardia and respiratory depression was higher in the intervention group.
CONCLUSIONS: Among intracerebral hemorrhage patients with a SBP ≥ 150 mmHg, a preset protocol using a remifentanil and dexmedetomidine-based standard guideline management significantly increased the SBP control rate at 1 h posttreatment compared with the standard guideline-based management. (ClinicalTrials.gov number: NCT03207100, Registration date: June 30, 2017).
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Anesthesiology - (2024) vom: 27. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Dong, Rui [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 27.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT03207100 Citation Status Publisher |
---|
doi: |
10.1097/ALN.0000000000004986 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370265696 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM370265696 | ||
003 | DE-627 | ||
005 | 20240329001600.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240329s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/ALN.0000000000004986 |2 doi | |
028 | 5 | 2 | |a pubmed24n1353.xml |
035 | |a (DE-627)NLM370265696 | ||
035 | |a (NLM)38537025 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Dong, Rui |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effects of an early intensive blood pressure-lowering strategy using remifentanil and dexmedetomidine in patients with spontaneous intracerebral hemorrhage |b a multicenter, prospective, superiority, randomized controlled trial |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 27.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a ClinicalTrials.gov: NCT03207100 | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Anesthesiologists. | ||
520 | |a BACKGROUND: Although it has been established that elevated blood pressure and its variability worsen outcomes in spontaneous intracerebral hemorrhage, antihypertensives use during the acute phase still lacks robust evidence. A blood pressure-lowering regimen using remifentanil and dexmedetomidine might be a reasonable therapeutic option given their analgesic and anti-sympathetic effects. The objective of this superiority trial was to validate the efficacy and safety of this blood pressure-lowering strategy that uses remifentanil and dexmedetomidine in patients with acute intracerebral hemorrhage | ||
520 | |a METHODS: In this multicenter, prospective, single-blinded, superiority randomized controlled trial, patients with intracerebral hemorrhage and systolic blood pressure (SBP) ≥150 mmHg were randomly allocated to the intervention group (a preset protocol with a standard guideline management using remifentanil and dexmedetomidine) or the control group (standard guideline-based management) to receive blood pressure-lowering treatment. The primary outcome was the SBP control rate (<140 mmHg) at 1 h posttreatment initiation. Secondary outcomes included blood pressure variability, neurologic function and clinical outcomes | ||
520 | |a RESULTS: A total of 338 patients were allocated to the intervention (n = 167) or control group (n = 171). The SBP control rate at 1 h posttreatment initiation in the intervention group was higher than that in controls (101/161, 62.7% vs. 66/166, 39.8%, difference 23.2%, 95% CI, 12.4 to 34.1%, P < 0.001). Analysis of secondary outcomes indicated that patients in the intervention group could effectively reduce agitation while achieving lighter sedation, but no improvement in clinical outcomes was observed. Regarding safety, the incidence of bradycardia and respiratory depression was higher in the intervention group | ||
520 | |a CONCLUSIONS: Among intracerebral hemorrhage patients with a SBP ≥ 150 mmHg, a preset protocol using a remifentanil and dexmedetomidine-based standard guideline management significantly increased the SBP control rate at 1 h posttreatment compared with the standard guideline-based management. (ClinicalTrials.gov number: NCT03207100, Registration date: June 30, 2017) | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Li, Fen |e verfasserin |4 aut | |
700 | 1 | |a Li, Bin |e verfasserin |4 aut | |
700 | 1 | |a Chen, Qiming |e verfasserin |4 aut | |
700 | 1 | |a Huang, Xianjian |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Jiehua |e verfasserin |4 aut | |
700 | 1 | |a Huang, Qibing |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Zeli |e verfasserin |4 aut | |
700 | 1 | |a Cao, Yunxing |e verfasserin |4 aut | |
700 | 1 | |a Yang, Mingbiao |e verfasserin |4 aut | |
700 | 1 | |a Li, Jianwei |e verfasserin |4 aut | |
700 | 1 | |a Li, Zhanfu |e verfasserin |4 aut | |
700 | 1 | |a Li, Cuiyu |e verfasserin |4 aut | |
700 | 1 | |a Liu, Guohua |e verfasserin |4 aut | |
700 | 1 | |a Zhong, Shu |e verfasserin |4 aut | |
700 | 1 | |a Feng, Guang |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Ming |e verfasserin |4 aut | |
700 | 1 | |a Xiao, Yumei |e verfasserin |4 aut | |
700 | 1 | |a Lin, Kangyue |e verfasserin |4 aut | |
700 | 1 | |a Shen, Yunlong |e verfasserin |4 aut | |
700 | 1 | |a Shao, Huanzhang |e verfasserin |4 aut | |
700 | 1 | |a Shi, Yuan |e verfasserin |4 aut | |
700 | 1 | |a Yu, Xiangyou |e verfasserin |4 aut | |
700 | 1 | |a Li, Xiaopeng |e verfasserin |4 aut | |
700 | 1 | |a Yao, Lan |e verfasserin |4 aut | |
700 | 1 | |a Du, Xinyu |e verfasserin |4 aut | |
700 | 1 | |a Xu, Ying |e verfasserin |4 aut | |
700 | 1 | |a Kang, Pei |e verfasserin |4 aut | |
700 | 1 | |a Gao, Guoyi |e verfasserin |4 aut | |
700 | 1 | |a Ouyang, Bin |e verfasserin |4 aut | |
700 | 1 | |a Chen, Wenjin |e verfasserin |4 aut | |
700 | 1 | |a Zeng, Zhenhua |e verfasserin |4 aut | |
700 | 1 | |a Chen, Pingyan |e verfasserin |4 aut | |
700 | 1 | |a Chen, Chunbo |e verfasserin |4 aut | |
700 | 1 | |a Yang, Hong |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Anesthesiology |d 1945 |g (2024) vom: 27. März |w (DE-627)NLM00001267X |x 1528-1175 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:27 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/ALN.0000000000004986 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 27 |c 03 |